输血相关急性肺损伤的免疫机制

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (5): 575-579.

输血相关急性肺损伤的免疫机制

李锐, 黄宇光

中国医学科学院,北京协和医学院,北京协和医院麻醉科,北京 100730

收稿日期:2012-06-12 修回日期:2012-09-13 出版日期:2013-05-26 发布日期:2013-05-22
通讯作者: 黄宇光,男,主任医师,教授,博导,研究方向:血液保护和慢性疼痛。Tel: 010-65294278 E-mail: pumchhyg@yahoo.com.cn
作者简介:李锐,男,博士研究生,研究方向:血液保护。Tel: 18810261615 E-mail: lrayd@sina.com

Immune mechanism of transfusion-related acute lung injury

LI Rui, HUANG Yu-guang

Department of Anesthesiology, Peking Union Medical College Hospital, CAMS and PUMC, Beijing 100730, China

Received:2012-06-12 Revised:2012-09-13 Online:2013-05-26 Published:2013-05-22

摘要/Abstract

摘要： 输血相关急性肺损伤(TRALI)是接受任何血制品期间或 6 h 内新出现的急性肺损伤,是输血相关发病和死亡最常见的原因之一。基础和临床研究均表明血制品输注后免疫启动是肺损伤必需的步骤,抗原抗体反应触发一系列事件导致TRALI,主要涉及血制品人类白细胞抗原(HLA)和中性粒细胞抗原(HNA)抗体。TRALI重在预防,未来发病机制仍将是其研究重点。

Abstract: TRALI is one type of new-onset acute lung injury that happens within 6 h of initiation of any blood transfusion. It is one of the most common causes of transfusion-related morbidity and mortality. Both basic and clinical researches have demonstrated that immune priming is a fundamental step for lung injury. Antigen-antibody reactions trigger a series of events that lead to TRALI, which mainly relate to HLA and HNA antibodies of blood products. The prevetion is very important for TRALI and research on mechanism of TRALI will be still a key point.

Key words: Transfusion-related acute lung injury, Immunology, Human lencocyte antigens, Human neutrophit antigen

中图分类号:

R563

李锐, 黄宇光. 输血相关急性肺损伤的免疫机制[J]. 中国临床药理学与治疗学, 2013, 18(5): 575-579.

LI Rui, HUANG Yu-guang. Immune mechanism of transfusion-related acute lung injury[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 575-579.

参考文献

[1] Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma[J]. Transfusion, 2009, 49(3): 440-452.
[2] Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008[J]. Transfusion, 2011, 51(10): 2102-2110.
[3] Bux J. Antibody-mediated (immune) transfusion-related acute lung injury[J]. Vox Sang, 2011, 100(1): 122-128.
[4] Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies[J]. Am Rev Respir Dis, 1983, 128(1): 185-189.
[5] Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician[J]. Anesth Analg, 2009, 108(3): 770-776.
[6] Flesch BK, Petershofen EK, Bux J. TRALI-new challenges for histocompatibility and immunogenetics in transfusion medicine[J]. Tissue Antigens, 2011, 78(1): 1-7.
[7] Muschter S, Berthold T, Greinacher A. Developments in the definition and clinical impact of human neutrophil antigens[J]. Curr Opin Hematol, 2011, 18(6): 452-460.
[8] Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury[J]. Transfusion, 1985, 25(6): 573-577.
[9] Kleinman SH, Triulzi DJ, Murphy EL, et al. The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or -negative components[J]. Transfusion, 2011, 51(10): 2078-2091.
[10] Sachs UJ, Wasel W, Bayat B, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies [J]. Blood, 2011, 117(2): 669-677.
[11] Gottschall JL, Triulzi DJ, Curtis B, et al. The frequency and specificity of human neutrophil antigen antibodies in a blood donor population[J]. Transfusion, 2011, 51(4): 820-827.
[12] Greinacher A, Wesche J, Hammer E, et al. Characterization of the human neutrophil alloantigen-3a [J]. Nat Med, 2010, 16(1): 45-48.
[13] Nakajima F, Nishimura M, Hashimoto S, et al. Role of anti-Nak(a) antibody, monocytes and platelets in the development of transfusion-related acute lung injury[J]. Vox Sang, 2008, 95(4): 318-323.
[14] Strait RT, Hicks W, Barasa N, et al. MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice[J]. J Exp Med, 2011, 208(12): 2525-2544.
[15] Wakamoto S, Fujihara M, Takahashi D, et al. Enhancement of endothelial permeability by coculture with peripheral blood mononuclear cells in the presence of HLA Class II antibody that was associated with transfusion-related acute lung injury[J]. Transfusion, 2011, 51(5): 993-1001.
[16] Logdberg LE, Vikulina T, Zimring JC, et al. Animal models of transfusion-related acute lung injury[J]. Transfus Med Rev, 2009, 23(1): 13-24.
[17] Quillen K, Medrano C, Adams S, et al. Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome[J]. Transfusion, 2011, 51(3): 504-510.
[18] Hashimoto S, Nakajima F, Kamada H, et al. Relationship of donor HLA antibody strength to the development of transfusion-related acute lung injury [J]. Transfusion, 2010, 50(12): 2582-2591.
[19] Fung YL, Kim M, Tabuchi A, et al. Recipient T lymphocytes modulate the severity of antibody-mediated transfusion-related acute lung injury[J]. Blood, 2010, 116(16): 3073-3079.
[20] Vlaar AP, Hofstra JJ, Kulik W, et al. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model [J]. Blood, 2010, 116(8): 1360-1368.
[21] Sachs UJ. Recent insights into the mechanism of transfusion-related acute lung injury[J]. Curr Opin Hematol, 2011, 18(6): 436-442.